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ABSTRACT
Introduction: Pre-eclampsia (PE) affects 2–3% of all
pregnancies and is a major cause of maternal and
perinatal morbidity and mortality. Prophylactic use of
low-dose aspirin in women at risk for PE may
substantially reduce the prevalence of the disease.
Effective screening for PE requiring delivery before
37 weeks (preterm PE) can be provided by a
combination of maternal factors, uterine artery
Doppler, mean arterial pressure, maternal serum
pregnancy-associated plasma protein A and placental
growth factor at 11–13 weeks’ gestation, with a
detection rate of 75% at a false-positive rate of 10%.
We present a protocol (V.6, date 25 January 2016) for
the ASpirin for evidence-based PREeclampsia
prevention (ASPRE) trial, which is a double-blinded,
placebo-controlled, randomised controlled trial (RCT)
that uses an effective PE screening programme to
determine whether low-dose aspirin given to women
from 11 to 13 weeks’ gestation will reduce the
incidence of preterm PE.
Methods and analysis: All eligible women attending
for their first trimester scan will be invited to
participate in the screening study for preterm PE.
Those found to be at high risk of developing preterm
PE will be invited to participate in the RCT. Further
scans will be conducted for assessment of fetal growth
and biomarkers. Pregnancy and neonatal outcomes will
be collected and analysed. The first enrolment for the
pilot study was in April 2014. As of April 2016, 26 670
women have been screened and 1760 recruited to the
RCT. The study is registered on the International
Standard Randomised Controlled Trial Number
(ISRCTN) registry.
Trial registration number: ISRCTN13633058.
BACKGROUND
Pre-eclampsia (PE) is an important cause of
maternal and perinatal mortality and mor-
bidity. There is extensive evidence that the
risk of adverse outcome in relation to PE is
much higher when the disease is severe and
of early onset requiring delivery before
37 weeks’ gestation (preterm PE), than at
term.1–4 A major challenge in modern obste-
trics is early identification of pregnancies at
high risk of preterm PE and undertaking the
necessary measures to improve placentation
and reduce the prevalence of the disease.
Prediction of preterm PE
Extensive research in the past 20 years,
mainly as a consequence of the shift in
screening for aneuploidies from the second
to the first trimester of pregnancy, has identi-
fied a series of early biophysical and bio-
chemical markers of impaired placentation.5
A combination of maternal demographic
characteristics, including medical and obstet-
ric history, uterine artery pulsatility index
(PI), mean arterial pressure (MAP) and
maternal serum pregnancy-associated plasma
protein-A (PAPP-A) and placental growth
factor (PlGF) at 11–13 weeks’ gestation can
Strengths and limitations of this study
▪ This is the largest multicentre, double-blinded,
randomised placebo-controlled trial to examine
the effect of aspirin in women who are high risk
of developing pre-eclampsia.
▪ The screening will occur in the first trimester as
to allow for the maximum benefit of aspirin.
▪ One hundred and fifty milligrams of aspirin will
be used to reduce the incidence of aspirin resist-
ance and maximise the effect.
▪ Follow-up of the offspring is limited to the early
postnatal phase.
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identify a high proportion of pregnancies at high risk
for PE.6 A recent study involving 58 800 singleton pre-
gnancies examined at 11–13 weeks’ gestation has fur-
ther refined the prediction algorithm for PE. Using this
algorithm, the estimated detection rate of preterm PE
was 75%, at a false-positive rate of 10%.6
Prevention of preterm PE
The prophylactic use of low-dose aspirin for prevention
of PE has been an important research question in
obstetrics for the past three decades. In 1979, Crandon
and Isherwood7 observed that nulliparous women who
had taken aspirin regularly during pregnancy were less
likely to have PE than those who did not. There have
been two meta-analyses published reporting that the
administration of low-dose aspirin in high-risk pregnan-
cies is associated with a decrease in the rate of PE.8 9
However, there are also other possible pathways which
lead to the development of PE among different risk
groups, and it is not known which risk factors or patho-
logical processes may be responsive to early initiation of
low-dose aspirin.
Initiation of low-dose aspirin in early pregnancy
In most studies that evaluated aspirin for the prevention
of PE, the initiation of treatment was at or after 16 weeks’
gestation. Examination of a small number of randomised
trials of low-dose aspirin in women at high risk for PE sug-
gests that the effectiveness of therapy is related to the ges-
tational age at the initiation of treatment. A meta-analysis
by Bujold et al9 reported that low-dose aspirin started at
16 weeks or earlier was associated with a significant reduc-
tion in the relative risk (RR) for PE (0.47, 95% CI 0.34 to
0.65) and fetal growth restriction (FGR; 0.44, 95% CI
0.30 to 0.65). In contrast, aspirin started after 16 weeks
did not have a significant benefit (PE: RR 0.81, 95% CI
0.63 to 1.03; FGR: RR 0.98, 95% CI 0.87 to 1.10). More
detailed analyses of these data on PE demonstrated that
low-dose aspirin started at or before 16 weeks’ gestation
was particularly effective in preventing preterm PE rather
than term PE (RR: 0.11, 95% CI 0.04 to 0.33 vs RR: 0.98,
95% CI 0.42 to 2.33).10
The small number and small size of individual trials
preclude definitive conclusions to be drawn regarding
the effectiveness of aspirin starting before 16 weeks and
the results need to be examined in a prospective major
randomised trial.
Aspirin resistance
There is evidence that ∼30%, 10% and 5% of pregnant
women are ‘aspirin resistant’ with dosage of 81, 121 and
162 mg, respectively.11 Furthermore, a retrospective cohort
study reported that women who were identified by the
PFA-100 test as being resistant to 81 mg of aspirin were less
likely to develop severe PE when the dose of aspirin was
increased from 81 to 162 mg, compared with those who
continued with 81 mg.12 Consequently, a trial investigating
the effectiveness of low-dose aspirin in the prevention of
preterm PE should use a dose closer to 160 than 80 mg.
Safety of low-dose aspirin
The relative safety of first trimester use of low-dose
aspirin has been demonstrated in large cohort and case–
control studies, which reported that the drug is not asso-
ciated with increase in risk of congenital heart defects or
other structural or developmental anomalies.13–16
Randomised studies reported that ∼10% of women
receiving low-dose aspirin presented with gastrointestinal
symptoms; however, there was no evidence of increase in
any type of maternal bleeding.17–19 Similarly, the best
evidence suggests that low-dose aspirin started before
16 weeks’ gestation does not increase the risk of placen-
tal abruption (RR 0.62, 95% CI 0.08 to 5.03).9 No add-
itional adverse effects related to epidural anaesthesia
have been reported in women taking low-dose aspirin
compared with those taking placebo.20
Prospective and case–control studies did not find an
association between daily consumption of 60–150 mg of
aspirin during the third trimester and antenatal closure of
the ductus arteriosus.21–23 A meta-analysis including more
than 26 000 women randomised to low-dose (80–150 mg)
aspirin or placebo/no treatment during pregnancy
demonstrated that the use of aspirin was not associated
with an increase in intraventricular haemorrhage or other
neonatal bleeding.24 On the basis of currently available evi-
dence, it would be reasonable to continue with low-dose
aspirin well into the third trimester of pregnancy.
HYPOTHESIS
We hypothesise that prophylactic low-dose aspirin admi-
nistered from first trimester of pregnancy in women at
increased risk for preterm PE will reduce the incidence
and severity of the disease.
AIM
To examine if the prophylactic use of low-dose aspirin
administered from the first trimester of pregnancy in
women at increased risk for preterm PE can reduce the
incidence and severity of the disease.
OBJECTIVES
Primary objective
To determine the efficacy of low-dose aspirin (150 mg
daily), given to high-risk women from 11–14 to
36 weeks’ gestation, in reducing the incidence of
preterm PE, requiring delivery before 37 weeks.
Secondary objectives
▸ To determine the effect of low-dose aspirin on
adverse outcome of pregnancy at <37 weeks.
– PE requiring delivery at <37 weeks;
– Small for gestational age (<5th centile) requiring
delivery at <37 weeks;
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– Miscarriage or stillbirth at <37 weeks;
– Placental abruption (clinically or on placental
examination) at <37 weeks;
– Composite of any of the above.
▸ To determine the effect of low-dose aspirin on
adverse outcome of pregnancy at <34 weeks.
– PE requiring delivery at <34 weeks;
– Small for gestational age (<5th centile) requiring
delivery at <34 weeks;
– Miscarriage or stillbirth at <34 weeks;
– Placental abruption (clinically or on placental
examination) at <34 weeks;
– Composite of any of the above.
▸ To determine the effect of low-dose aspirin on
adverse outcome of pregnancy at >37 weeks.
– PE requiring delivery at >37 weeks;
– Small for gestational age (<5th centile) requiring
delivery at >37 weeks;
– Miscarriage or stillbirth at >37 weeks;
– Placental abruption (clinically or on placental
examination) at >37 weeks;
– Composite of any of the above.
▸ To determine the effect of low-dose aspirin on neo-
natal mortality and morbidity.
– Neonatal intensive care unit admission;
– Intraventricular haemorrhage (IVH) grade II or
above—defined as bleeding into the ventricles
○ Grade II (moderate)—IVH occupies <50% of the
lateral ventricle volume,
○ Grade III (severe)—IVH occupies >50% of the
lateral ventricle volume,
○ Grade IV (severe)—haemorrhagic infarction in
periventricular white matter ipsilateral to a
large IVH;
– Ventilation—defined as need of positive pressure
(continuous positive airway pressure (CPAP) or
nasal CPAP) or intubation;
– Neonatal sepsis—confirmed bacteraemia in
cultures;
– Anaemia—defined as low haemoglobin and/or
haematocrit requiring blood transfusion;
– Respiratory distress syndrome—defined as need of
surfactant and ventilation as a result of prematurity;
– Necrotising enterocolitis (NEC) requiring surgical
intervention;
– NEC is defined by a combination of clinical, radio-
logical and laboratory features:
Systemic signs—apnoea, bradycardia, tempera-
ture instability, hypotension.
Intestinal signs—abdominal distension, gastric
residuals, bloody stools, absent bowel sounds,
abdominal tenderness, peritonitis.
Radiological signs—pneumatosis intestinalis or
portal venous air, pneumoperitoneum.
Laboratory changes—metabolic and or respira-
tory acidosis, thrombocytopaenia, disseminated
intravascular coagulation.
– Composite of any of the above.
▸ To determine the effect of low-dose aspirin on the
incidence of neonatal birth weight below the 3rd, 5th
and 10th centiles.
– Birth weight will be recorded in the participants’
medical notes, and birthweight percentile for ges-
tational age at delivery is calculated using a
normal range derived from our population.25
▸ To determine the effect of low-dose aspirin on the
incidence of stillbirth or neonatal death.
– Owing to any cause;
– Ascribed to PE or FGR;
– In association with maternal or neonatal bleeding.
▸ To determine the effect of low-dose aspirin on the
incidence of spontaneous preterm delivery at <34
and <37 weeks.
– Spontaneous delivery at <34 weeks (early preterm)
and at <37 weeks (total preterm) includes those
with spontaneous onset of labour and those with
preterm prelabour rupture of membranes.
CENTRES
There are 13 academic hospitals participating in the
trial. There are six centres in the UK; three in Spain;
and one in each of Milan, Brussels, Greece and Israel.
DESIGN
There are three components to the study: an internal
pilot study, a screening quality study and a screening
study followed by a double-blinded randomised placebo-
controlled trial. Informed consent will be obtained by a
trained healthcare professional who is a member of the
study team at each particular centre.
Internal pilot study
The main study has been preceded by a 2-month pilot
study, undertaken at King’s College Hospital. In total,
1106 participants have been consented into the screen-
ing study and 56 participants to the randomised con-
trolled trial (RCT). This pilot study has been used to
assess the feasibility of recruitment to the screening
study and RCT, and the ability of the centre to ensure
successful compliance. A review by the ASpirin for
evidence-based PREeclampsia prevention (ASPRE)
Independent Data Monitoring Committee (IDMC) and
Trial Steering Committee (TSC) of the internal pilot
study has demonstrated the study has been successful
with respect to recruitment to the screening study and
RCT; however, it has also highlighted the complexity of
the main ASPRE trial and confirmed the need for
enhanced quality systems to be in place in advance of
starting the main ASPRE trial in order to ensure the
quality of pivotal data.
Screening quality study
A screening quality study, with a minimum recruitment
period of 1–3 months (dependent on sites’ perform-
ance) at each site, has been introduced to precede the
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main ASPRE trial. The aim of this study is to establish
systems that will monitor quality of the measurement of
uterine artery PI, MAP, PAPP-A and PlGF in a more
detailed, formalised manner at sites and use these
systems to assess quality, identify areas for improvement
and, where required, implement strategies to improve
quality, for example, retraining. This is based on the
Down’s syndrome screening quality assurance support
service (DQASS) system that has been successful for
improving the quality of the ultrasound and biochemical
measurements in the National Health Service (NHS)
fetal anomaly screening programme.
Recruitment rates have also been monitored.
Furthermore, an assessment of data quality was made
by the trial team at University College London
Comprehensive Clinical Trials Unit (UCL CCTU) and
any site-specific operational issues, which could not have
been foreseen by the site assessment process, were iden-
tified, and addressed in advance of starting the main
ASPRE trial.
Screening study and RCT
Following receipt of the results of the screening study,
eligible high-risk women will be invited to take part in
the RCT designated by the trial teams. It is anticipated
that 10% of the population will screen positive for
preterm PE and be invited to participate in the trial
(figure 1).
INCLUSION AND EXCLUSION CRITERIA
Screening phase inclusion criteria
▸ Age >18 years;
▸ Singleton pregnancy;
▸ Live fetus at 11–13 weeks of gestation;
▸ English, Italian, Spanish, French, Dutch or Greek
speaking (otherwise interpreters will be used);
▸ Informed and written consent.
Screening phase exclusion criteria
▸ Multiple pregnancy;
▸ Pregnancies complicated by major fetal abnormality
identified at the 11–13 weeks assessment;
▸ Women who are unconscious or severely ill, those
with learning difficulties, or serious mental illness;
▸ Age <18 years.
Randomisation inclusion criteria following screening
▸ Screening phase inclusion criteria fulfilment;
▸ High risk for preterm PE at 11–13 weeks by the algo-
rithm combining maternal history and characteristics,
biophysical findings (MAP and uterine artery PI) and
biochemical factors (PAPP-A and PlGF);
Randomisation exclusion criteria following screening
▸ Women taking low-dose aspirin regularly;
▸ Bleeding disorders such as Von Willebrand’s disease;
▸ Peptic ulceration;
▸ Hypersensitivity to aspirin or already on long-term
non-steroidal anti-inflammatory medication;
▸ Concurrent participation in another drug trial or at
any time within the previous 28 days;
▸ Any other reason the clinical investigators think will
prevent the potential participant from complying
with the trial protocol.
METHODS
We will recruit women attending for their routine
first scan in pregnancy at 11–13 weeks’ gestation in the
UK, Spain, Belgium, Italy, Greece and Israel. All eli-
gible women attending for their routine first scan in
pregnancy at 11–13 weeks’ gestation are invited to take
part. For the screening quality study and the screening
study, the patient information sheet (PIS) will be
sent with the appointment letter to all potential
participants.
In women who agree to participate in the screening
quality study, after obtaining informed consent, we
measure the maternal MAP by automated devices,26 use
transabdominal colour Doppler ultrasound to visualise
the left and right uterine artery and measure the PI in
each vessel and calculate the mean PI.27 Maternal serum
PlGF is measured in the same blood sample taken for the
measurement of PAPP-A, using automated machines that
provide reproducible results (DELFIA Xpress system,
PerkinElmer Life and Analytical Sciences, Waltham,
Massachusetts, USA) as part of the routine screening for
Down’s syndrome. Participants enrolled in the screening
quality study will not be informed of their risk of develop-
ing PE and will be managed according to routine stand-
ard of care at the site they attend. The principal
investigators at each site are doctors who received their
training by KHN and follow the Fetal Medicine
Foundation (FMF) guidelines on how to undertake the
appropriate measurements.
In women who agree to participate in the screening
study of the main trial, after obtaining informed
consent, we measure maternal MAP, uterine artery PI,
PAPP-A and PlGF as described above. Following screen-
ing for preterm PE, high-risk women will be invited to
take part in the RCT by designated members of the trial
teams. Women eligible to participate in this trial will
receive written information on the test drug and provide
informed consent. When randomised, participants will
be assigned a randomisation code. The randomisation
codes will determine who receives placebo or aspirin
150 mg. The investigational medicinal product (IMP)
supplier (Mawdsley Brooks and Co) will keep and store
the randomisation code list. All participants, the princi-
pal investigator and clinical trial pharmacy will remain
blind to trial drug allocation.
Data collection
Participant data for this study will be entered into an
electronic case report form (CRF). For participants in
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the RCT the CRF will be printed and signed by the
enrolling researcher.
RANDOMISATION
Randomisation will be performed using a web-based
system Sealed Envelope. The website randomly assigns
participants to a randomisation code which corresponds
to treatment packs with the same code at a given site.
Each treatment pack will only be identified by a random-
isation code. The treatment allocation will only be
revealed to the researchers after completion of the study
or where clinically essential.
CONCEALMENT OF ALLOCATION
Mawdsley Brooks and Co will provide labelling (for all
cartons and blister sheets) ensuring complete blinding of
the IMP to all investigators and participants in the study,
which includes the principal investigator, participating
research doctors, pharmacists at the local clinical trial
pharmacy, project managers and others involved in the
Figure 1 Flow chart of participants in the screening study and the randomised controlled trial. *Clinical visits at 19–24 and 30–
37 weeks will only be performed on screen-negative participants at sites where a scan is performed by the fetal medicine unit as
part of the routine clinical care pathway at either of these times. FGR, fetal growth restriction; PE, pre-eclampsia.
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trial. They are all blinded to the IMP allocation. Matching
placebo tablets will be identical to the intervention
(aspirin) in such parameters as size, thickness, physical
properties and appearance. A film coating will be applied
to the placebo tablets for aesthetic and taste reasons.
Mawdsley Brooks and Co will keep the randomisation
code list confidential to maintain the blind; however, the
randomisation code list will be transferred to Sealed
Envelope to enable online randomisation and unblinding
service to be established.
INTERVENTION
Participants will take one tablet per night of either
aspirin 150 mg or matched placebo. Participants will be
asked to stop taking tablets at 36 weeks’ gestation or, in
the event of early delivery, at the onset of labour
(maximum duration of 25 weeks). The aspirin tablets
will be film-coated, to be taken orally once per night
from enrolment until 36 weeks’ gestation.
STUDY ASSESSMENT
The study procedure by visit has been outlined in table 1.
Laboratory tests
At the time of the 11–13 weeks scan, 20 mL of maternal
blood will be taken for the measurement of PAPP-A and
PlGF using automated machines that provide reprodu-
cible results (DELFIA Xpress system, PerkinElmer Life
and Analytical Sciences, Waltham, Massachusetts, USA).
The remaining serum and plasma will be stored at −80°
C for future studies of potential biochemical markers
for adverse pregnancy outcomes.
PARTICIPANT COMPLIANCE
Participants will be asked to bring their trial medication
to each clinical visit; IMP compliance will be assessed by
trial teams by counting remaining tablets at each
follow-up visit and asking about compliance at telephone
follow-up. Compliance with other aspects of the trial
protocol will also be assessed. Participants will be
encouraged to report any concerns or side effects in a
diary for review at each trial visit.
OUTCOMES
Primary outcome
▸ Incidence of preterm PE (delivery at <37 weeks).
PE will be defined as per the International Society for
the Study of Hypertension in Pregnancy.29 The systolic
blood pressure should be 140 mm Hg or more and/or
the diastolic blood pressure should be 90 mm Hg or
more on at least two occasions 4 hours apart developing
after 20 weeks of gestation in previously normotensive
women (blood pressure <140/90 mm Hg) and there
should be proteinuria of 300 mg or more in 24 hours or
urinary protein creatinine ratio of 30 mg/mmol or more
or two readings of at least ++ on dipstick analysis of
midstream or catheter urine specimens if no 24-hour
collection is available. The efficacy will be assessed by
the development of PE at any gestation after 20 weeks of
pregnancy as defined above.
Secondary outcomes
▸ As defined above in the Secondary objectives section.
Collection of pregnancy and neonatal outcomes
Data on pregnancy and neonatal outcomes will be col-
lected from the hospital maternity records or their
general medical practitioners. The obstetric records of
the randomised women with pre-existing or
pregnancy-associated hypertension will be examined to
determine if the condition was chronic hypertension, PE
or gestational hypertension. In the event, neonates are
admitted to special care baby unit (SCBU), additional
neonatal outcomes will be collected from the discharge
summary of SCBU.
SIDE EFFECTS AND ADVERSE EVENTS REPORTING
Adverse event (AE) and reaction (AR) data are not
being collected for participants of the screening quality
study, or the screen-negative participants in main ASPRE
RCT, as they are non-Clinical Trial of an Investigational
Medicinal Product (CTIMP), which do not expose parti-
cipants to any additional risk over and above that of
routine clinical care.
Safety evaluations will be conducted at each of the
RCT participants’ follow-up visits. AEs include any
unwanted side effects, sensitivity reactions, abnormal
laboratory results, injury or intercurrent illnesses, and
may be expected or unexpected. The period for AE
reporting will be from the time of first dose until 30 days
postfinal IMP administration. The participants will be
followed up by a telephone interview 30 days after the
last dose of IMP. These AEs will be recorded on the elec-
tronic CRF and do not need to be reported to the
sponsor. The participants are instructed to contact a
member of the trial team if there are any concerns
regarding their medication.
Serious AEs/ARs (SAEs/SARs) occurring in the
mother or baby from the time a participant is rando-
mised until 30 days after stopping taking the IMP or
until 30 days after delivery or until 30 days after the esti-
mated due date, respectively, whichever is later, will be
reported to the sponsor using the trial documentation.
The standard definition of an SAE will be used.30
For the purposes of this study, the following events are
included as protocol-defined exceptions to SAE report-
ing should only be reported to the sponsor as an SAE/
SAR if the investigator believes the event is a result of
the ASPRE intervention: hospitalisation for maternal or
fetal observation, including minor bleeding episodes;
preterm delivery (spontaneous, for maternal or fetal
indication); miscarriage; stillbirth or neonatal death;
admission of baby to neonatal intensive care unit;
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termination for fetal or maternal indication. If the event
is deemed to be part of the routine progress of the preg-
nancy concerned, these events should be reported to
the sponsor as a protocol-defined exception to SAE
reporting, within the respective reporting timelines.
STATISTICAL ANALYSIS PLAN INCLUDING SAMPLE SIZE
AND POWER CALCULATION
The sample size calculation is based on a 76% detection
rate of the first trimester combined screening for preterm
PE at a screen-positive rate of 10%. With the aim to achieve
a significant 50% reduction in the prevalence of preterm
PE from 7.6% in the placebo group to 3.8% in the aspirin
group, with a power of 90%, and 5% significance level, it is
necessary to randomise 1600 high-risk pregnancies. If we
allow for 10% loss to follow-up, it will be necessary to ran-
domise a total of 1760 high-risk pregnancies, 880 women
in each of the aspirin and placebo arms. On the assump-
tion that 60% of high-risk pregnancies will agree to ran-
domisation, we need to identify 2933 high-risk pregnancies
(which will constitute 10% of the screened population).
We will therefore have to recruit a total of 29 330 pregnan-
cies to the screening study.
Type of analysis and statistical tests
The primary analysis will be a mixed-effects logistic
regression analysis of the incidence of preterm PE
Table 1 Summary of the study visits
Screening
visit
Randomisation
visit
First
telephone
interview
First
follow-up
visit
Second
telephone
interview
Second
follow-up
visit
Third
follow-up
visit
Third
telephone
interview
Gestation 11–13 weeks 11–14 weeks 16 weeks 19–24 weeks 28 weeks 32–34 weeks 36 weeks 30 days
after the
last dose
of IMP
Patient
information
and
characteristics
√
Informed
consent
√ √
Measurement
of weight and
height
√ √ √ √
Measurement
of MAP
√ √ √ √
Fetal
ultrasound
scan
√ √ √ √
Measurement
of uterine
artery PI
√ √ √ √
Measurement
of PAPP-A
and PlGF
√ √ √
Check
concomitant
medications
√ √ √ √ √ √
IMP
dispensing
√ √
Ensure
compliance
√ √ √ √ √
Check side
effects/
adverse
events and
review of
diary card
√ √ √ √ √ √
Discontinue
IMP
√
IMP, investigational medicinal product; MAP, mean arterial pressure; PlGF, placental growth factor; PAPP-A, pregnancy-associated plasma
protein-A; PI, pulsatility index.
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with fixed effects for treatment and risk, and random
effects for centre. A choice of transformation of risk
(eg, logit transform) or grouping into levels will be
made on the basis of a blinded review of the data.
The treatment effect will be tested at the two-sided
5% level. Ninety-five per cent CIs will be produced for
the proportions developing preterm PE in each of the
two groups and for the treatment effect (active–
placebo).
Planned secondary analysis of the primary outcome
will include a survival analysis of the time to delivery
with PE treating births for other causes as censoring.
Prespecified baseline variables considered to be predict-
ive will be included as appropriate. Their interactions
with the treatment effect will be investigated. Gestational
age at randomisation and its interaction with treatment
will also be investigated. This analysis of treatment inter-
actions will be considered as exploratory.
Descriptive statistics
A full set of descriptive statistics for all variables, overall
and by treatment group, will be produced. Graphical dis-
plays will be produced as appropriate.
Secondary analysis
Secondary outcomes will be compared across treatment
groups using appropriate tests. p Values and 99% CIs
will be produced for treatment effects. No corrections
will be made for multiplicity.
Safety
The incidence rates of AEs and SAEs and their relation-
ship to trial drugs will be summarised by treatment
group. The proportion of women discontinuing treat-
ment will be summarised by reason and by treatment
group.
COMMITTEE OVERSIGHTS
The IDMC is independent from the trial and is respon-
sible for monitoring the progress of the trial including
recruitment, protocol adherence, SAEs and side effects
of treatment as well as the difference between the trial
treatments on the primary outcome measures. They are
the only oversight body that has access to unblinded
accumulating comparative data. The IDMC is respon-
sible for safeguarding the interests of trial participants,
monitoring the accumulating data and making recom-
mendations to the TSC on whether the trial should con-
tinue as planned.
The TSC is the independent group responsible for
oversight of the trial in order to safeguard the interests
of trial participants. The TSC provides advice to the
chief investigator, co-chief investigator, UCL CCTU, the
funder and sponsor on all aspects of the trial through its
independent chair.
ETHICS AND DISSEMINATION
The study will be conducted in accordance with the
principles of Good Clinical Practice. A favourable ethical
opinion was obtained from London-Fulham Research
Ethics Committee, reference number 13/LO/1479.
Subsequent approval by individual ethical committee
and competent authority was granted. Results will be
published in peer-reviewed journals and disseminated at
international conferences.
DISCUSSION
The traditional approach to screening for PE is to iden-
tify risk factors from maternal demographic character-
istics and medical history, but such an approach can
identify only 35% of total PE and about 40% of preterm
PE at false-positive rate of about 10%.31 32
In a proposed new approach to antenatal care, the
potential value of an integrated clinic at 11–13 weeks’
gestation in which maternal characteristics and history
are combined with the results of a series of biophysical
and biochemical markers to assess the risk for a wide
range of pregnancy complications has been extensively
documented.33 Effective screening for preterm PE can
be achieved in this clinic with a detection rate of about
76% at a false-positive rate of 10%.6 There is a sugges-
tion that the prevalence of PE can be halved by prescrib-
ing pregnant women low-dose aspirin before 16 weeks’
gestation,9 and by using an enhanced screening
approach using maternal demographics and history with
biochemical and biophysical markers, these women can
be identified effectively and entered into a double-
blinded randomised placebo-controlled trial to assess
whether low-dose aspirin can truly reduce the preva-
lence of preterm PE when given in the first trimester of
pregnancy.
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